Yes, oxybutynin can cause constipation as a well-established anticholinergic side effect.
Oxybutynin, as an anticholinergic medication, is known to cause constipation through its mechanism of blocking muscarinic receptors in the gastrointestinal tract, which decreases intestinal motility. This is explicitly stated in FDA labeling and multiple clinical guidelines 1.
Mechanism and Clinical Evidence
The FDA drug label clearly warns that "the concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects" 1. The anticholinergic properties of oxybutynin decrease gastrointestinal motility by blocking acetylcholine at muscarinic receptors, particularly M3 receptors in the gut 2.
Clinical guidelines from NCCN Palliative Care explicitly list anticholinergic drugs (including antispasmodics like oxybutynin) among medications known to cause constipation 3. The 2018 ESMO guidelines similarly identify anticholinergics as common constipation-inducing medications 4.
Quantified Risk
A meta-analysis of randomized controlled trials specifically examining overactive bladder medications found that oxybutynin carries an odds ratio of 2.34 (95% CI 1.31-4.16) for constipation compared to placebo 5. This means patients on oxybutynin are more than twice as likely to experience constipation.
Clinical Presentation
In pediatric enuresis guidelines, constipation is identified as "the most bothersome side effect" of oxybutynin treatment 6. The guideline specifically recommends excluding or treating constipation before initiating anticholinergic therapy, and notes that constipation may herald a slowly decreasing anti-enuretic effect.
Practical Management Considerations
Before Starting Oxybutynin:
- Assess baseline bowel function and exclude pre-existing constipation 6
- Document current stool frequency and consistency
- Review other constipating medications
During Treatment:
- Monitor for constipation development, particularly in elderly patients who are at higher risk 1
- The FDA label warns to use oxybutynin with caution in patients with decreased gastrointestinal motility, ulcerative colitis, or intestinal atony 1
- Watch for complications: the drug may suppress intestinal motility to the point of producing paralytic ileus in susceptible patients 1
If Constipation Develops:
- Consider dose reduction or drug discontinuation 1
- Initiate stimulant laxatives (e.g., senna, bisacodyl) rather than just stool softeners 3
- Increase fluid intake and encourage physical activity when appropriate 3
- Consider switching to alternative medications with lower constipation risk (e.g., mirabegron, a β3 agonist, showed minimal effect on constipation in comparative studies) 7
Important Caveats
The risk is dose-dependent and cumulative with other anticholinergic medications. Patients taking multiple anticholinergic drugs face increased frequency and severity of constipation 1. The FDA specifically warns about this additive effect.
Extended-release formulations of oxybutynin may have similar constipation rates to immediate-release forms, though they offer other tolerability advantages 8. The constipation risk persists regardless of formulation.
In vulnerable populations—particularly the frail elderly, those with pre-existing bowel disorders, or patients on opioids—the constipation risk is substantially higher and requires proactive management 3, 1.